|
000
| 01076nam 2200229za 4500 |
|---|
| 001 | 9.699196 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20210625000255 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 150407s2014||||xxc|||||o f|0| 0 eng d |
|---|
| 020 | |a978-1-100-23517-2 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-105/2014E-PDF |
|---|
| 110 | 2 |aPublic Health Agency of Canada. |
|---|
| 245 | 10|aLiterature review on serogroup B invasive meningococcal disease : |h[electronic resource]|bepidemiology, multicomponent meningococcal B vaccine characteristics and other factors for consideration. |
|---|
| 246 | 1 |iAt head of title: |aAdvisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) |
|---|
| 260 | |aOttawa - Ontario : |bPublic Health Agency of Canada |cc2014. |
|---|
| 300 | |a153p.|btables |
|---|
| 590 | |a14-19|b2014-05-09 |
|---|
| 775 | 08|tRevue de la littérature sur la méningococcie invasive du sérogroupe B : |w(CaOODSP)9.643157 |
|---|
| 856 | 40|ahttp://publications.gc.ca|qPDF|s1.94 MB|uhttps://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-105-2014-eng.pdf |
|---|